`
`Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
`
`Drug Databases (httP.s://www.fda.gov/Drugs/lnformationOnDrug~).
`
`Orange Book: Approved Drug Products
`with Therapeutic Equivalence
`Evaluations
`
`Home (index.cfm?resetfields=1). I Back to Search Results
`
`Product Details for NDA 020226
`
`NAPHCON-A (NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE)_
`0.025%;0.3%
`Marketing Status: Over-the-counter
`
`Active Ingredient: NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE
`Proprietary Name: NAPHCON-A
`Dosage Form; Route of Administration: SOLUTION/DROPS; OPHTHALMIC
`Strength: 0.025%;0.3%
`Reference Listed Drug: Yes
`Reference Standard: Yes
`TE Code:
`Application Number: N020226
`Product Number: 00 1
`Approval Date: Jun 8, 1994
`Applicant Holder Full Name: ALCON LABORATORIES INC
`Marketing Status: Over-the-counter
`Patent and Exclusivity Information (gatent info.cfm?
`Product No=001 &Aggi No=020226&AImLtY.P-e=N).
`
`https://www.accessdata.fda.gov/scripts/cder/ob/results _product..cfm?Appl_ Type=N&Appl_ No=020226#41039
`
`1/1
`
`Eye Therapies Exhibit 2078, 1 of 1
`Slayback v. Eye Therapies - IPR2022-00142
`
`